WRLD A.LIVE

23:002 reports

• Eli Lilly (LLY) shares skyrocket, what you need to know TradingView
• Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases 24/7 Wall St.

22:006 reports

• GLP-1 therapies show promise in reducing comorbid claims: GreenShield Benefits and Pensions Monitor
• GLP-1 drugs may help patients shed regained weight after bariatric surgery Medical Xpress
• Eli Lilly and Co Stock (LLY) Opened Up by 7.54% on Oct 29: Drivers Behind the Movement TradingKey
• Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers BioSpace
• (LLY) Eli Lilly Expects 2026 Revenue Range $91.0B to $92.0B, vs. FactSet Est of $88.82B www.marketscreener.com
• Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue Estimates Yahoo Finance

21:003 reports

• Strong Results, Guidance Boost Eli Lilly Shares Ahead of Earnings Yahoo Finance
• Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump Reuters
• Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound WSJ

20:002 reports

• Earnings live updates: Eli Lilly stock pops as strong GLP-1 drug demand lifts results, ServiceNow stock plunges Yahoo Finance
• Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying. MarketWatch

19:003 reports

• Eli Lilly profits surge on demand for weight-loss drugs Financial Times
• Lilly Raises Sales Guidance, Widening Its Lead in Obesity Market Bloomberg.com
• Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio Eli Lilly

18:003 reports

• 3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead 24/7 Wall St.
• Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again CNBC
• Everyone’s going on — and off — GLP-1s. What’s that doing to your health? Radio-Canada

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:001 report

• GLP-1 weight-loss pills vs injections: How they compare and why you shouldn't get the pills online CNA Lifestyle

06:001 report

• Understanding Glucagon Like Peptides: Their Role and Medical Uses BusinessWorld Online

05:002 reports

• Rising GLP-1 costs push employers to reconsider weight loss coverage Employee Benefit News
• To cover or not to cover: HR’s GLP-1 dilemma Canadian HR Reporter

04:00nothing heard

03:002 reports

• 16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage 24/7 Wall St.
• GLP-1 insurance coverage: 5 things to know in 2026 qz.com

02:002 reports

• Context-dependent pharmacological effects of GLP-1 receptor agonists in breast cancer from molecular mechanisms to clinical safety Frontiers
• Retatrutide beats Ozempic on weight loss, blood sugar control, study says USA Today

01:002 reports

• How Lilly's Retatrutide Compared With Ozempic in a Head-to-Head Diabetes Trial Around Prague
• Lilly's triple G overpowers Ozempic in diabetes trial pharmaphorum